Published: 27 June 2022
Author(s): Raquel López-Vilella, Víctor Donoso Trenado, Borja Guerrero Cervera, Ignacio Sánchez-Lázaro, Luis Almenar Bonet
Issue: October 2022
Section: Letter to the Editor

Since the recent past, sodium-glucose cotransporter type 2 inhibitors (SGLT2i) have been recommended as mainstay therapy for patients with chronic heart failure (HF) and reduced ejection fraction (HFrEF) due to their positive effects on mortality, clinical events, and quality of life. (1) Thus, clinical practice guidelines have recommended its use regardless of a history of diabetes. (2) On the other hand, the appropriateness of its introduction during the acute phase of HF is less well defined.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.